NCT03888755View on ClinicalTrials.gov

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 18, 2015

Primary Completion Date

February 12, 2016

Study Completion Date

February 12, 2016

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

Icatibant

Participants will receive icatibant 30 mg SC injection in the abdominal area.

Trial Locations (8)

Unknown

Fukushima Medical University Hospital, Fukushima

Hiroshima University Hospital, Hiroshima

Kobe University Hospital, Kobe

Saiseikai Kumamoto Hospital, Kumamoto

Niigata City General Hospital, Niigata

Nihon University Itabashi Hospital, Tokyo

Tomakomai City Hospital, Tomakomai

Yokohama City University Hospital, Yokohama

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT03888755 - A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants | Biotech Hunter | Biotech Hunter